Martin Møller

Chairman of the Board since April 2022, member of the Board of Directors since 2021

Education: MA in comparative literature from the University of Copenhagen

Background: Worked for more than 20 years at the international management consulting firm McKinsey & Company, specializing in healthcare, biotech, pharmaceuticals and life sciences, since 2007 as a Partner and since 2013 as a Senior Partner. In that role, he has advised companies globally on strategy, growth and transformations, including drug development and innovation.

Other ongoing assignments: Board member in Immunovia AB and Rehaler ApS

Independence: Independent in relation to both the Company and executive management as well as larger shareholders

Scandion Oncology shares and warrants
6,266 shares